Clinical Trial Update: Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib [Phase 3]

View source ↗

Summary

Phase 3 trial comparing temsirolimus to sorafenib as second-line therapy in advanced renal cell carcinoma after failure of first-line sunitinib; results have be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)
• Torisel (Temsirolimus)

Snippet

Sponsor: Pfizer | Conditions: Renal Cell Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2013-03-07